Dr. Balazs Halmos

Dr. Balazs Halmos, a thoracic medical oncologist at Montefiore Einstein Cancer Center, joins the discussion on crucial findings from the World Conference on Lung Cancer 2025. He highlights the FLAURA2 trial, showcasing how osimertinib combined with chemotherapy enhances survival for EGFR-positive non-small cell lung cancer patients. Halmos delves into the HARMONi trial's unexpected results with a bi-specific antibody and the significance of ctDNA. He wraps up with insights on crizotinib's role in ALK-positive cases and the evolving landscape of precision oncology.